Brief: Vascular Biogenics Says Newly Granted European Patent Protects Vbl Therapeutics' Anti-Mospd2 Antibodies For Inflammation Until At Least July 2036
13/10/2020 01:28
Oct 12 (Reuters) - Vascular Biogenics Ltd VBLT.O :
* VASCULAR BIOGENICS LTD - NEWLY GRANTED EUROPEAN PATENT
PROTECTS
VBL THERAPEUTICS' ANTI-MOSPD2 ANTIBODIES FOR INFLAMMATION UNTIL
AT LEAST JULY 2036
* VASCULAR BIOGENICS LTD -
Source text for Eikon: ID:nGNX2QCrdD
Further company coverage: VBLT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives